Rapport Therapeutics (RAPP) Depreciation & Amortization (CF) (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Depreciation & Amortization (CF) of $227000.0 for Q1 2026, down 6.97% year-over-year from $244000.0 in Q1 2025, and down 14.34% quarter-over-quarter from $265000.0 in Q4 2025.
Powered by 
Analysis
Rapport Therapeutics (RAPP) Depreciation & Amortization (CF) (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Depreciation & Amortization (CF) for 4 consecutive years, with $227000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 6.97% year-over-year to $227000.0; the TTM figure through Mar 2026 stood at $1.0 million (up 7.41% YoY), while the FY2025 annual figure was $1.0 million, up 21.22% from the prior year.
- Depreciation & Amortization (CF) fell to $227000.0 in Q1 2026 per RAPP's latest filing, from $265000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $265000.0 in Q4 2025 and bottomed at $23000.0 in Q3 2023.
- Historically, Depreciation & Amortization (CF) has averaged $188250.0 across 4 years, with a median of $223000.0 in 2024.
- Annual changes were most pronounced in 2024 — Depreciation & Amortization (CF) jumped 852.17% — and 2026, when it retreated 6.97%.
- Rapport Therapeutics' Depreciation & Amortization (CF) stood at $53000.0 in 2023, then jumped by 390.57% to $260000.0 in 2024, then advanced by 1.92% to $265000.0 in 2025, then retreated by 14.34% to $227000.0 in 2026.
- Business Quant data shows RAPP's Depreciation & Amortization (CF) at $227000.0 in Q1 2026, $265000.0 in Q4 2025, and $256000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Rapport Therapeutics | 2.17 Bn | 2.17 Bn | - | 212,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 212,000.00 |
| Mar 31, 2026 | 227,000.00 |
| Dec 31, 2025 | 265,000.00 |
| Sep 30, 2025 | 256,000.00 |
| Jun 30, 2025 | 252,000.00 |
| Mar 31, 2025 | 244,000.00 |
| Dec 31, 2024 | 260,000.00 |
| Sep 30, 2024 | 219,000.00 |
| Jun 30, 2024 | 208,000.00 |
| Mar 31, 2024 | 152,000.00 |
| Dec 31, 2023 | 53,000.00 |
| Sep 30, 2023 | 23,000.00 |